Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma

•A validated UPLC-MS/MS assay for the measurement of taletrectinib in dog plasma.•Low sample volume is needed, as well as simple sample preparation by protein precipitation.•A high sensitivity (LLOQ 0.2 ng/mL) was achieved.•Excellent linearity was achieved between 0.2–200 ng/mL.•The assay was succes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2024-10, Vol.1247, p.124305, Article 124305
Hauptverfasser: Zhu, Yunfeng, Wang, Fangkai, Wang, Xin, Cheng, Ya, Wang, Xingyu, Fan, Ali, Chang, Jiawei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 124305
container_title Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
container_volume 1247
creator Zhu, Yunfeng
Wang, Fangkai
Wang, Xin
Cheng, Ya
Wang, Xingyu
Fan, Ali
Chang, Jiawei
description •A validated UPLC-MS/MS assay for the measurement of taletrectinib in dog plasma.•Low sample volume is needed, as well as simple sample preparation by protein precipitation.•A high sensitivity (LLOQ 0.2 ng/mL) was achieved.•Excellent linearity was achieved between 0.2–200 ng/mL.•The assay was successfully applied to a pharmacokinetic study in dogs. Taletrectinib is a potent selective ROS and pan-NTRK tyrosine kinase inhibitor (TKI) and has been developed to treat non-small cell lung cancer (NSCLC). To facilitate pharmacokinetic and toxicokinetic studies of taletrectinib, we developed a procedure for ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect the plasma level of taletrectinib in dogs. This assay procedure was validated in compliance with FDA guidance. The dog plasma samples were spiked with internal standard (IS), followed by protein precipitation, and analyzed using a Waters ACQUITY BEH C18 column coupled to a Thermo triple quadrupole mass spectrometer. Separation was executed using the acetonitrile-0.1 % formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Taletrectinib and IS were monitored by multiple reaction monitoring (MRM) with m/z 406.2 > 349.2 and m/z 441.2 > 138.1, respectively. The procedure demonstrated excellent linearity with a correlation coefficient greater than 0.999 within the concentration range of 0.2–200 ng/mL. The inter- and intra-day accuracy ranged from −5.25 % to 5.26 %, and the precision was below 6.39 %. Acetonitrile-mediated protein precipitation showed high extraction efficiency and a recovery above 85 %. The procedure was then applied to quantify taletrectinib in beagle dog plasma after oral and intravenous doses and achieved success. The obtained pharmacokinetic parameters indicated high bioavailability of taletrectinib (>85 %) and extensive tissue distribution (>40 L/kg).
doi_str_mv 10.1016/j.jchromb.2024.124305
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106732550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023224003143</els_id><sourcerecordid>3106732550</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-7948a19cfe165f5c1622daa72fcb24e9f4686b4439f48f700ceed8070bbe18b83</originalsourceid><addsrcrecordid>eNqFkclu2zAQhoWiRZOmfYQWPPYim4skSqciMLohzoI4AXojuIxiupSokrQLv0afuDTs9NrTLPhmfsz8RfGe4BnBpJlvZhu9Dn5QM4ppNSO0Yrh-UZyTlrOS8ebHy5zXHJeYMnpWvIlxgzHhmLPXxRnraMdI3Z0Xfy6nyVktk_Uj8j0a4bfbIwM7cH4Cg-Ro0E46a2TK1ePdclFer-bXKzRAWnuDeh_QtJZhkNr_tCMkq1FMW7M_LLu_XZH5zcP9FbLj2iqbMpykgxRAJztalftIgXxygIx_QpOTcZBvi1e9dBHeneJF8fjl88PiW7m8_fp9cbksdb41lbyrWkk63QNp6r7WpKHUSMlprxWtoOurpm1UVbGctT3HWAOYFnOsFJBWteyi-HjcOwX_awsxicFGDc7JEfw2CkZwwxmta5zR-ojq4GMM0Isp2EGGvSBYHOwQG3GyQxzsEEc78tyHk8RWDWD-TT3_PwOfjgDkQ3cWgojawqjB2MOPhPH2PxJ_AYLLn50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106732550</pqid></control><display><type>article</type><title>Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zhu, Yunfeng ; Wang, Fangkai ; Wang, Xin ; Cheng, Ya ; Wang, Xingyu ; Fan, Ali ; Chang, Jiawei</creator><creatorcontrib>Zhu, Yunfeng ; Wang, Fangkai ; Wang, Xin ; Cheng, Ya ; Wang, Xingyu ; Fan, Ali ; Chang, Jiawei</creatorcontrib><description>•A validated UPLC-MS/MS assay for the measurement of taletrectinib in dog plasma.•Low sample volume is needed, as well as simple sample preparation by protein precipitation.•A high sensitivity (LLOQ 0.2 ng/mL) was achieved.•Excellent linearity was achieved between 0.2–200 ng/mL.•The assay was successfully applied to a pharmacokinetic study in dogs. Taletrectinib is a potent selective ROS and pan-NTRK tyrosine kinase inhibitor (TKI) and has been developed to treat non-small cell lung cancer (NSCLC). To facilitate pharmacokinetic and toxicokinetic studies of taletrectinib, we developed a procedure for ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect the plasma level of taletrectinib in dogs. This assay procedure was validated in compliance with FDA guidance. The dog plasma samples were spiked with internal standard (IS), followed by protein precipitation, and analyzed using a Waters ACQUITY BEH C18 column coupled to a Thermo triple quadrupole mass spectrometer. Separation was executed using the acetonitrile-0.1 % formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Taletrectinib and IS were monitored by multiple reaction monitoring (MRM) with m/z 406.2 &gt; 349.2 and m/z 441.2 &gt; 138.1, respectively. The procedure demonstrated excellent linearity with a correlation coefficient greater than 0.999 within the concentration range of 0.2–200 ng/mL. The inter- and intra-day accuracy ranged from −5.25 % to 5.26 %, and the precision was below 6.39 %. Acetonitrile-mediated protein precipitation showed high extraction efficiency and a recovery above 85 %. The procedure was then applied to quantify taletrectinib in beagle dog plasma after oral and intravenous doses and achieved success. The obtained pharmacokinetic parameters indicated high bioavailability of taletrectinib (&gt;85 %) and extensive tissue distribution (&gt;40 L/kg).</description><identifier>ISSN: 1570-0232</identifier><identifier>ISSN: 1873-376X</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2024.124305</identifier><identifier>PMID: 39293159</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Chromatography, High Pressure Liquid - methods ; Dogs ; Limit of Detection ; Linear Models ; Liquid Chromatography-Mass Spectrometry ; Male ; Pharmacokinetics ; Protein Kinase Inhibitors - blood ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacokinetics ; Proto-Oncogene Proteins - antagonists &amp; inhibitors ; Proto-Oncogene Proteins - blood ; Reproducibility of Results ; ROS1/NTRK inhibitor ; Taletrectinib ; Tandem Mass Spectrometry - methods ; UPLC-MS/MS</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-10, Vol.1247, p.124305, Article 124305</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-7948a19cfe165f5c1622daa72fcb24e9f4686b4439f48f700ceed8070bbe18b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jchromb.2024.124305$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39293159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Yunfeng</creatorcontrib><creatorcontrib>Wang, Fangkai</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Cheng, Ya</creatorcontrib><creatorcontrib>Wang, Xingyu</creatorcontrib><creatorcontrib>Fan, Ali</creatorcontrib><creatorcontrib>Chang, Jiawei</creatorcontrib><title>Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>•A validated UPLC-MS/MS assay for the measurement of taletrectinib in dog plasma.•Low sample volume is needed, as well as simple sample preparation by protein precipitation.•A high sensitivity (LLOQ 0.2 ng/mL) was achieved.•Excellent linearity was achieved between 0.2–200 ng/mL.•The assay was successfully applied to a pharmacokinetic study in dogs. Taletrectinib is a potent selective ROS and pan-NTRK tyrosine kinase inhibitor (TKI) and has been developed to treat non-small cell lung cancer (NSCLC). To facilitate pharmacokinetic and toxicokinetic studies of taletrectinib, we developed a procedure for ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect the plasma level of taletrectinib in dogs. This assay procedure was validated in compliance with FDA guidance. The dog plasma samples were spiked with internal standard (IS), followed by protein precipitation, and analyzed using a Waters ACQUITY BEH C18 column coupled to a Thermo triple quadrupole mass spectrometer. Separation was executed using the acetonitrile-0.1 % formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Taletrectinib and IS were monitored by multiple reaction monitoring (MRM) with m/z 406.2 &gt; 349.2 and m/z 441.2 &gt; 138.1, respectively. The procedure demonstrated excellent linearity with a correlation coefficient greater than 0.999 within the concentration range of 0.2–200 ng/mL. The inter- and intra-day accuracy ranged from −5.25 % to 5.26 %, and the precision was below 6.39 %. Acetonitrile-mediated protein precipitation showed high extraction efficiency and a recovery above 85 %. The procedure was then applied to quantify taletrectinib in beagle dog plasma after oral and intravenous doses and achieved success. The obtained pharmacokinetic parameters indicated high bioavailability of taletrectinib (&gt;85 %) and extensive tissue distribution (&gt;40 L/kg).</description><subject>Animals</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Dogs</subject><subject>Limit of Detection</subject><subject>Linear Models</subject><subject>Liquid Chromatography-Mass Spectrometry</subject><subject>Male</subject><subject>Pharmacokinetics</subject><subject>Protein Kinase Inhibitors - blood</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacokinetics</subject><subject>Proto-Oncogene Proteins - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins - blood</subject><subject>Reproducibility of Results</subject><subject>ROS1/NTRK inhibitor</subject><subject>Taletrectinib</subject><subject>Tandem Mass Spectrometry - methods</subject><subject>UPLC-MS/MS</subject><issn>1570-0232</issn><issn>1873-376X</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkclu2zAQhoWiRZOmfYQWPPYim4skSqciMLohzoI4AXojuIxiupSokrQLv0afuDTs9NrTLPhmfsz8RfGe4BnBpJlvZhu9Dn5QM4ppNSO0Yrh-UZyTlrOS8ebHy5zXHJeYMnpWvIlxgzHhmLPXxRnraMdI3Z0Xfy6nyVktk_Uj8j0a4bfbIwM7cH4Cg-Ro0E46a2TK1ePdclFer-bXKzRAWnuDeh_QtJZhkNr_tCMkq1FMW7M_LLu_XZH5zcP9FbLj2iqbMpykgxRAJztalftIgXxygIx_QpOTcZBvi1e9dBHeneJF8fjl88PiW7m8_fp9cbksdb41lbyrWkk63QNp6r7WpKHUSMlprxWtoOurpm1UVbGctT3HWAOYFnOsFJBWteyi-HjcOwX_awsxicFGDc7JEfw2CkZwwxmta5zR-ojq4GMM0Isp2EGGvSBYHOwQG3GyQxzsEEc78tyHk8RWDWD-TT3_PwOfjgDkQ3cWgojawqjB2MOPhPH2PxJ_AYLLn50</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>Zhu, Yunfeng</creator><creator>Wang, Fangkai</creator><creator>Wang, Xin</creator><creator>Cheng, Ya</creator><creator>Wang, Xingyu</creator><creator>Fan, Ali</creator><creator>Chang, Jiawei</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241015</creationdate><title>Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma</title><author>Zhu, Yunfeng ; Wang, Fangkai ; Wang, Xin ; Cheng, Ya ; Wang, Xingyu ; Fan, Ali ; Chang, Jiawei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-7948a19cfe165f5c1622daa72fcb24e9f4686b4439f48f700ceed8070bbe18b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Dogs</topic><topic>Limit of Detection</topic><topic>Linear Models</topic><topic>Liquid Chromatography-Mass Spectrometry</topic><topic>Male</topic><topic>Pharmacokinetics</topic><topic>Protein Kinase Inhibitors - blood</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacokinetics</topic><topic>Proto-Oncogene Proteins - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins - blood</topic><topic>Reproducibility of Results</topic><topic>ROS1/NTRK inhibitor</topic><topic>Taletrectinib</topic><topic>Tandem Mass Spectrometry - methods</topic><topic>UPLC-MS/MS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Yunfeng</creatorcontrib><creatorcontrib>Wang, Fangkai</creatorcontrib><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Cheng, Ya</creatorcontrib><creatorcontrib>Wang, Xingyu</creatorcontrib><creatorcontrib>Fan, Ali</creatorcontrib><creatorcontrib>Chang, Jiawei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Yunfeng</au><au>Wang, Fangkai</au><au>Wang, Xin</au><au>Cheng, Ya</au><au>Wang, Xingyu</au><au>Fan, Ali</au><au>Chang, Jiawei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2024-10-15</date><risdate>2024</risdate><volume>1247</volume><spage>124305</spage><pages>124305-</pages><artnum>124305</artnum><issn>1570-0232</issn><issn>1873-376X</issn><eissn>1873-376X</eissn><abstract>•A validated UPLC-MS/MS assay for the measurement of taletrectinib in dog plasma.•Low sample volume is needed, as well as simple sample preparation by protein precipitation.•A high sensitivity (LLOQ 0.2 ng/mL) was achieved.•Excellent linearity was achieved between 0.2–200 ng/mL.•The assay was successfully applied to a pharmacokinetic study in dogs. Taletrectinib is a potent selective ROS and pan-NTRK tyrosine kinase inhibitor (TKI) and has been developed to treat non-small cell lung cancer (NSCLC). To facilitate pharmacokinetic and toxicokinetic studies of taletrectinib, we developed a procedure for ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect the plasma level of taletrectinib in dogs. This assay procedure was validated in compliance with FDA guidance. The dog plasma samples were spiked with internal standard (IS), followed by protein precipitation, and analyzed using a Waters ACQUITY BEH C18 column coupled to a Thermo triple quadrupole mass spectrometer. Separation was executed using the acetonitrile-0.1 % formic acid solution with gradient elution, at a flow rate of 0.4 mL/min. Taletrectinib and IS were monitored by multiple reaction monitoring (MRM) with m/z 406.2 &gt; 349.2 and m/z 441.2 &gt; 138.1, respectively. The procedure demonstrated excellent linearity with a correlation coefficient greater than 0.999 within the concentration range of 0.2–200 ng/mL. The inter- and intra-day accuracy ranged from −5.25 % to 5.26 %, and the precision was below 6.39 %. Acetonitrile-mediated protein precipitation showed high extraction efficiency and a recovery above 85 %. The procedure was then applied to quantify taletrectinib in beagle dog plasma after oral and intravenous doses and achieved success. The obtained pharmacokinetic parameters indicated high bioavailability of taletrectinib (&gt;85 %) and extensive tissue distribution (&gt;40 L/kg).</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39293159</pmid><doi>10.1016/j.jchromb.2024.124305</doi></addata></record>
fulltext fulltext
identifier ISSN: 1570-0232
ispartof Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-10, Vol.1247, p.124305, Article 124305
issn 1570-0232
1873-376X
1873-376X
language eng
recordid cdi_proquest_miscellaneous_3106732550
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Chromatography, High Pressure Liquid - methods
Dogs
Limit of Detection
Linear Models
Liquid Chromatography-Mass Spectrometry
Male
Pharmacokinetics
Protein Kinase Inhibitors - blood
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacokinetics
Proto-Oncogene Proteins - antagonists & inhibitors
Proto-Oncogene Proteins - blood
Reproducibility of Results
ROS1/NTRK inhibitor
Taletrectinib
Tandem Mass Spectrometry - methods
UPLC-MS/MS
title Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T01%3A27%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20newly%20developed%20and%20validated%20UPLC-MS/MS%20method%20for%20pharmacokinetic%20study%20of%20ROS1/NTRK%20inhibitor%20taletrectinib%20in%20beagle%20dog%20plasma&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Zhu,%20Yunfeng&rft.date=2024-10-15&rft.volume=1247&rft.spage=124305&rft.pages=124305-&rft.artnum=124305&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2024.124305&rft_dat=%3Cproquest_cross%3E3106732550%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3106732550&rft_id=info:pmid/39293159&rft_els_id=S1570023224003143&rfr_iscdi=true